VALORY Study of Valsartan/Hydrochlorizide for Patients Who do Not Respond Adequately to Olmesartan Medoxomil
Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of valsartan 160 mg/HCTZ 25 mg in patients not adequately responding
to monotherapy with olmesartan medoxomil 40 mg or combination therapy with olmesartan
medoxomil 20 mg plus HCTZ 12.5 mg by testing the hypothesis that valsartan 160 mg/HCTZ 25 mg
significantly reduces the trough mean sitting diastolic blood pressure (MSDBP) after a 4-week
treatment in the nonresponder population.